Breckenridge Announces Launch of its 10mg strength for Everolimus Tablets (generic for Afinitor®)
BERLIN, Conn., Oct. 1, 2021 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces today that it has launched the 10mg strength of Everolimus Tablets (generic for Afinitor®). The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application. This product was developed in collaboration with Natco Pharma Limited. According to industry sales data, the 10mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021. Breckenridge previously launched its Everolimus tablets in 2.5mg, 5mg and 7.5mg strengths during the second quarter of 2021.
For further information, please contact:
*All brand names and trademarks are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/breckenridge-announces-launch-of-its-10mg-strength-for-everolimus-tablets-generic-for-afinitor-301389699.html
SOURCE Breckenridge Pharmaceutical, Inc.